Aptys helps companies which develop peptide-based products as an adviser on peptide design, pre-clinical/clinical strategy, and pharmaceutical development strategy. Some of our customers: a biopharmaceutical company developing LHRH agonists; a biotech company for the development of a new peptide for neuronal reconstruction; and two other biotech companies developing new entities.
Aptys’ involvement in peptide drug development originally stems from the expertise of Dr. François Boutignon, co-founder of the company. Previously, François served as Vice-President R&D at Europeptides where he was involved in several aspects of the preclinical and clinical development of several peptides and analogues (growth hormones and GnRH agonists/antagonists). During these years, François filed two patents and advanced two injectable sustained release formulations to clinical phases II and III.